1. In Vivo
  2. >>Business Strategy

Overhauling Teva: Conversations With Jeremy Levin And Michael Hayden

 
• By Wendy Diller

Teva CEO Jeremy Levin and the CSO he hired, Michael Hayden, want to re-focus the company on innovative R&D and selective generics opportunities, and that means an overhaul of the R&D organization and new priorities for business development. Levin and Hayden spoke to IN VIVO about their goals and shaping these activities following a widely anticipated investor briefing on December 11 in New York City.

Since he became CEO of Teva Pharmaceutical Industries Ltd. last May, Jeremy Levin, DPhil, MB, has spent considerable time articulating his vision of a reshaped company. The overhaul is significant. After phenomenal growth, which saw Teva’s sales more than double since 2006, Levin and Teva’s board believed that the company had veered off course.

Not that Teva is in immediate danger. Its financials attest to its health, as Levin and others emphasize. But in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

More from In Vivo

AI In The Loop: How Astellas Is Accelerating Oncology Drug Discovery

 
• By Jo Shorthouse

Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.

BioBytes: Israeli-US Startup Introduces Platform For Accelerated Clinical Data Analysis

 
• By David Wild

A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.

The Dementia Disparity: Rethinking Alzheimer’s Through The Female Lens

 
• By Ian Taylor

Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.